HCG or Clomid for Fertility on TRT? (TRT Q&As)
Timeline
Dr. O’Connor discusses how long-term testosterone can suppress the reproductive axis and explains why HCG may be used differently depending on age, duration of TRT, prior steroid exposure, and the degree of testicular suppression. He also discusses his approach when fertility becomes the primary goal.
Dr. O’Connor explains that withdrawal after potent anabolic steroid use can be difficult and discusses PCT, gradual transition, and why recovery varies considerably between men. He also notes that some men may consider TRT rather than experiencing a severe hormonal crash, particularly after substantial prior androgen exposure.
Dr. O’Connor discusses potency versus sterility, noting that testosterone may remain potent for a long time but that contamination is a separate concern. He describes roughly 90 days as a more conservative practical timeframe rather than assuming an opened vial remains safe indefinitely.
A 38-year-old man reports a severe reaction after stopping testosterone and Anavar, including loss of muscle, insomnia, chest pain, and a resting heart rate around 30 beats per minute. Dr. O’Connor says testosterone and Anavar should not be viewed as treatment for profound bradycardia and emphasizes further cardiac evaluation, potentially including an electrophysiologist.
Dr. O’Connor responds to a member who describes significant personal difficulties and says he appears to be doing better. He encourages continued participation in the meetings so they can keep reviewing his situation and providing educational information as he moves forward.
The member reports AST and ALT rising dramatically after starting Ostarine and Cardarine. Dr. O’Connor considers the elevations concerning, discusses stopping the agents and repeating laboratory testing, and emphasizes medical evaluation to make sure there is not another liver problem contributing to the abnormal results.
Video Summary
This mailbag discussion focuses on questions that arise once testosterone therapy has been established for an extended period. It explains how long-term stability differs from early-phase changes and why dramatic shifts become less common over time. Ongoing treatment is framed as maintenance rather than continuous optimization.
A central portion examines how expectations should evolve as therapy matures. The episode discusses why consistent symptom control, rather than progressive gains, is often the appropriate goal. Long-term variability is contextualized to avoid unnecessary concern.
The closing segment reinforces testosterone therapy as sustained clinical care. Routine monitoring, proportional responses, and realistic expectations are emphasized. Hormone therapy is positioned as supporting long-term stability rather than ongoing escalation.
Drug Callouts
Condition Callouts
Key Takeaways
- Long-term testosterone therapy emphasizes stability rather than continual change.
- Expectations should evolve after initial adjustment.
- Some variability remains normal over time.
- Maintenance goals reduce unnecessary concern.
- Routine follow-up supports sustained benefit.